RRML - Co-expression of the CBFβ-MYH11 and BCR-ABL fusion genes in chronic myeloid leukaemia

ISSN online: 2284-5623

ISSN-L: 1841-6624

Rejection rate (2020): 75%

Română English

Journal Metrics

Impact Factor 0.5
Five Year Impact Factor 0.5
JCI 0.12

Advanced search

Top 10 downloaded articles
- February 2024 -
Anti-thyroid peroxidase (TPO) ... 18
Romanian Review of Laboratory ... 14
Recomandarea comună EFLM-COLA... 13
Identification of shared hub g... 12
Challenges in prophylactic the... 10
Approaching Risk Management in... 9
Monocyte to high-density lipop... 8
Understanding the key differen... 7
Understanding the pathogenesis... 7
Atellica CH 930 chemistry anal... 6

Log in

Concept, Design & Programming
Dr. Adrian Man

Nr. 23(2)/2015 DOI:10.1515/rrlm-2015-0013

Co-expression of the CBFβ-MYH11 and BCR-ABL fusion genes in chronic myeloid leukaemia

Roxana Popescu, Angela Dăscălescu, Cătălin Dănăilă, Doramina Ghiorghiu, Mihaela Zlei, Anca Ivanov, Adriana Sireteanu, Eusebiu Vlad Gorduza, Doina Azoicăi


The coexistence of t(9;22) and inv(16) has been described in a very limited number of cases of CML, de novo or therapy-related AML. We report a patient with CML who presented both inversion of chromosome 16 and Philadelphia chromosome and evolved towards the blast phase under treatment with Imatinib. Laboratory diagnosis and monitoring was made by flow cytometry, conventional cytogenetics and molecular genetics techniques. The inv(16), detected by karyotyping in the Philadelphia chromosome positive clone at the moment of the blast transformation, was retrospectively assessed by means of real-time PCR, and was proved to have been present since diagnosis. The bone marrow biopsy performed in the blast phase of CML confirmed the presence of blasts belonging to the myeloid lineage, with indications of monocytic differentiation, frequently associated with inv(16). Moreover, the case also associated a F359V tyrosine kinase domain mutation, resulting in intermediate resistance to Imatinib and Nilotinib, which imposed therapy-switch to Dasatinib. In our case the evolution was progressive, followed by death due to lack of response to tyrosine kinase inhibitors, 18 months after diagnosis. The coexistence of t(9;22) and inv(16) in CML seems to be associated with an aggressive clinical evolution and resistance to tyrosine kinase inhibitor therapy. Due to the very small number of cases described in literature, therapeutic decisions are still difficult for patients displaying these abnormalities.

Keywords: chronic myeloid leukaemia, Philadelphia chromosome, inv(16), tyrosine kinase domain mutation

Received: 12.11.2014
Accepted: 13.4.2015
Published: 29.4.2015

  PDF Download full text PDF
(1046 KB)
How to cite
Popescu R, Dăscălescu A, Dănăilă C, Ghiorghiu D, Zlei M, Ivanov A, et al. Co-expression of the CBFβ-MYH11 and BCR-ABL fusion genes in chronic myeloid leukaemia. Rev Romana Med Lab. 2015;23(2):221-30. DOI:10.1515/rrlm-2015-0013